Free tool
FAERS Monitor: Alvesco
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021658 or its brand name (Alvesco, Ciclesonide). Reports on generic versions are filed under their own applications.
Reports
11,143
Serious
10,133
91% of reports
Hospitalization
5,251
Death reported
567
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthma5,034
- dyspnoea3,973
- wheezing3,021
- cough2,157
- therapeutic product effect incomplete2,118
- loss of personal independence in daily activities1,647
- obstructive airways disorder1,440
- pneumonia1,420
- sleep disorder due to a general medical condition1,275
- productive cough1,195
- drug ineffective1,136
- fatigue1,063
- malaise1,012
- chest discomfort908
- nasopharyngitis898
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 5 |
| 2007 | 8 |
| 2008 | 36 |
| 2009 | 71 |
| 2010 | 114 |
| 2011 | 179 |
| 2012 | 201 |
| 2013 | 208 |
| 2014 | 225 |
| 2015 | 293 |
| 2016 | 443 |
| 2017 | 413 |
| 2018 | 600 |
| 2019 | 951 |
| 2020 | 1,306 |
| 2021 | 1,966 |
| 2022 | 893 |
| 2023 | 1,048 |
| 2024 | 884 |
| 2025 | 775 |
| 2026 | 524 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,016 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| obstructive airways disorderSignal | 1,440 | 280.6 | 266.3 | 349,207 |
| sleep disorder due to a general medical conditionSignal | 1,275 | 153.1 | 145.1 | 178,235 |
| wheezingSignal | 3,021 | 101.3 | 98.1 | 285,338 |
| asthmaSignal | 5,034 | 87.9 | 86.1 | 415,606 |
| loss of personal independence in daily activitiesSignal | 1,647 | 67.0 | 64.0 | 103,553 |
| therapeutic product effect incompleteSignal | 2,118 | 57.9 | 55.7 | 115,228 |
| productive coughSignal | 1,195 | 48.4 | 45.9 | 54,209 |
| chest discomfortSignal | 908 | 16.9 | 15.9 | 13,492 |
| coughSignal | 2,157 | 14.6 | 14.1 | 27,518 |
| dyspnoeaSignal | 3,973 | 13.3 | 13.0 | 46,242 |
| nasopharyngitisSignal | 898 | 9.2 | 8.7 | 6,612 |
| pneumoniaSignal | 1,420 | 8.3 | 7.9 | 9,227 |
| malaiseSignal | 1,012 | 4.4 | 4.1 | 2,670 |
| fatigueSignal | 1,063 | 2.6 | 2.4 | 1,064 |
| drug ineffective | 1,136 | 1.6 | 1.5 | 292 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.